Here are relevant reports on : virtual-human-market
-
Human Microbiome Manufacturing Services Market by Type (Fermentation & Downstream Processing, Strain Development & Optimization), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease) - Global Forecast to 2031
The global Human Microbiome Manufacturing Services market, valued at US$0.09 billion in 2024, stood at US$0.11 billion in 2025 and is projected to advance at a resilient CAGR of 16.7% from 2025 to 2031, culminating in a forecasted valuation of US$0.27 billion by the end of the period. Growing demand for specialized capabilities, such as anaerobic fermentation, microbial process scale-up, formulation, and fill-finish, is fueling broader adoption of human microbiome manufacturing services.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Electrical SCADA Market by Architecture (Hardware, Software, and Services), Component (Master Terminal unit, Remote Terminal unit, Human Machine Interface), Application (Generation, Transmission, and Distribution), and Region - Global Forecast to 2022
The electrical SCADA market is expected to grow from an estimated USD 2.29 Billion in 2017 to USD 3.29 Billion by 2022, at a CAGR of 7.48%, during the forecast period. This growth can be attributed to factors such as increased investments in electrical networks and government initiatives toward the adoption of industrial automation. To enable an in-depth understanding of the competitive landscape, the report includes the profiles of some of the top players in the electrical SCADA market. These players include ABB (Switzerland), Schneider (France), Rockwell Automation (US), Yokogawa (Japan), Honeywell (US), Siemens (Germany), Larsen & Toubro (India), Mitsubishi (Japan), Emerson (US), Open system International (US), Advanced Control System (US), and Bentek Systems (Canada). These players adopted various strategies such as new product launches, contracts & agreements, and investments and expansions, to increase their global presence and market share.
- Published: January 2018
- Price: $ 4950
- TOC Available:
-
Human Microbiome Drugs Market by Type (Live Biotherapeutic Products, Fecal Microbiota-derived Therapeutics), Disease (Gastrointestinal, Infectious), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2031
The human microbiome drugs market, valued at US$0.09 billion in 2024, stood at US$0.35 billion in 2025 and is projected to advance at a resilient CAGR of 35.2% from 2025 to 2031, culminating in a forecasted valuation of US$2.13 billion by the end of the period. The human microbiome drugs market is growing, driven by the increasing clinical success of live biotherapeutic products, rising prevalence of chronic and recurrent diseases, and expanding therapeutic applications beyond gastrointestinal disorders into metabolic, immune, and neurological conditions.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Disclosure Management Market by Business Function (Finance, Legal, Marketing and Communication, Compliance, Procurement, and Human Resource), Component (Software and Services), Deployment Type, Organization Size, and Vertical - Global forecast to 2022
The disclosure management market accounted for USD 433.0 Million in 2016 and is projected to reach USD 1,066.0 Million by 2022, growing at a Compound Annual Growth Rate (CAGR) of 16.7% during 2017–2022. The major growth drivers of the disclosure management market include the increasing need to comply with regulatory bodies, and globalization of businesses. The base year considered for this report is 2016, and the market forecast period considered is 2017–2022. The major vendors providing disclosure management software and services are SAP (Germany), Oracle (US), Certent (US), IRIS Business Services (India), Workiva (US), CoreFiling (UK), DataTracks (India), LucaNet (Germany), OCR Services (US), Trintech (Australia), and Lecorpio (US).
- Published: March 2018
- Price: $ 4950
- TOC Available:
-
North America Probiotics Market by Product Type (Functional Food & Beverages, Dietary Supplements, and Feed), Ingredient (Bacteria and Yeast), End User (Human and Animal), Distribution Channel, and Region - Forecast to 2030
The North America probiotics market is estimated to be USD 14.78 billion in 2025 and is projected to reach USD 21.92 billion by 2030, at a CAGR of 8.2% from 2025 to 2030. The Key ADM (US), Probi USA Inc. (US), Danone North America Public Benefit Corporation (US), International Flavors & Fragrances Inc. (US), Nestle USA (US), Lifeway Foods, Inc. (US), Lactalis American Group, Inc. (US), Kerry Group plc. (Ireland), Now Foods (US), Nature’s Bounty (US), Renewlife (US), Garden of Life (US), Jarrow Formulas, Inc. (US), Kevita (US), and Chobani, LLC. (US).
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
North America Human Microbiome Market By Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
North America Human Microbiome market, valued at US$0.43 billion in 2024, stood at US$0.78 billion in 2025 and is projected to advance at a resilient CAGR of 32.2% from 2025 to 2031, culminating in a forecasted valuation of US$4.15 billion by the end of the period. New startups in the US and Canada are driving innovation across microbiome therapeutics and diagnostics.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Europe Probiotics Market by Product Type (Functional Food & Beverages, Dietary Supplements, and Feed), Ingredient (Bacteria and Yeast), End User (Human and Animal), Distribution Channel, and Region - Forecast to 2030
The Europe probiotics market is estimated to be USD 15.73 billion in 2025 and is projected to reach USD 20.56 billion by 2030, registering at a CAGR of 5.5% from 2025 to 2030. The key players include Danone S.A. (France), Probi AB (Sweden), Nestlé S.A. (Switzerland), Kerry Group plc (Ireland), BioGaia AB (Sweden), Bio-K Plus International Inc. (Canada), Daflorn Probiotics Ltd. (Bulgaria), Yakult Honsha Co., Ltd. (Japan), Arla Foods (Denmark), and AB-Biotics S.A. (Spain).
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Global Albumin Market, by Product (Human Serum Albumin, Bovine Albumin, Recombinant Serum Albumin) by Application (Therapeutic, Drug Delivery, Culture Media, Vaccine Ingredient) by Region - Forecast to 2022
The global albumin market is projected to grow at a CAGR of around 6% during the forecast period (2017-2022). Factors such as the high demand of albumin in R&D activities, rising non-therapeutic application of albumin, development of plant based albumin, rising production of immunoglobulins, and rise in plasma collection are driving the market. However, the stringent regulations, limited reimbursement, and irrational uses and adverse effects associated with albumin are the factors restraining the growth of this market.
- Published: December 2026
- Price: $ 4950
- TOC Available:
-
Human Capital Management Market by Software (Core HR, Workforce Management, HR Analytics, and Applicant Tracking System), Services (Professional Services and Managed Services), Deployment Model, Organization Size - Global Forecast to 2029
The Human Capital Management market size is projected to reach USD 41.3 billion by 2029 at a Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period. Some of the key players operating in the HCM market are – Workday (US), UKG (US), Oracle (US), SAP (Germany), Dayforce (US), ADP (US), Paylocity (US), Paycom (US), Cornerstone (US), and Microsoft (US).
- Published: April 2024
- Price: $ 4950
- TOC Available:
-
Cell Expansion Market by Product (Consumables (Media, Sera, Reagents, Vessels), Equipment (Cell Expansion Systems, Bioreactors, Incubators)), Cell Type (Human, Animal (CHO, mESCs)), Application (Vaccines, mAbs, CGT), End User - Global Forecast to 2029
The global cell expansion market, valued at US$12.7 billion in 2023, stood at US$14.3 billion in 2024 and is projected to advance at a resilient CAGR of 13.3% from 2024 to 2029, culminating in a forecasted valuation of US$26.7 billion by the end of the period. Growth of the cell expansion market can be attributed to factors such as the booming biopharmaceutical industry, increased investments in research and development for the advancement of biopharmaceutical industry, rising need of advanced biopharmaceuticals, and increasing GMP certification for cell therapy manufacturing facilities.
- Published: March 2024
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
